Literature DB >> 21463972

Chronic pulmonary infection with Stenotrophomonas maltophilia and lung function in patients with cystic fibrosis.

C S Dalbøge1, C R Hansen, T Pressler, N Høiby, H K Johansen.   

Abstract

BACKGROUND: The clinical consequences of chronic Stenotrophomonas maltophilia infection in cystic fibrosis (CF) patient are still unclear.
METHOD: All patients treated in the Copenhagen CF centre (N=278) from 1 January 2008 to 31 December 2009 were included. Each patient chronically infected with S. maltophilia for at least 2 years without any other chronic Gram-negative infection were matched to two non-infected CF controls.
RESULTS: Twenty-one patients were chronically infected with S. maltophilia during the 2-year study period. Fifteen were infected for at least 2 years. The patients in the S. maltophilia group had a steeper decline (-3.2%/year vs. -0.3%/year) in FEV(1) compared to the non-infected CF controls (P=0.03). The rate of decline was the same as observed 3 years before the patients became chronically infected. DISCUSSIONS: Chronic infection with S. maltophilia does not lead to a steeper decline in lung function when compared to the period before chronic infection.
Copyright © 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21463972     DOI: 10.1016/j.jcf.2011.03.006

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  17 in total

Review 1.  Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.

Authors:  Reshma Amin; Valerie Waters
Journal:  Cochrane Database Syst Rev       Date:  2016-07-14

2.  Stenotrophomonas maltophilia Differential Gene Expression in Synthetic Cystic Fibrosis Sputum Reveals Shared and Cystic Fibrosis Strain-Specific Responses to the Sputum Environment.

Authors:  Graham G Willsey; Korin Eckstrom; Annette E LaBauve; Lauren A Hinkel; Kristin Schutz; Robert J Meagher; John J LiPuma; Matthew J Wargo
Journal:  J Bacteriol       Date:  2019-07-10       Impact factor: 3.490

3.  Resistance evolution can disrupt antibiotic exposure protection through competitive exclusion of the protective species.

Authors:  Angus M Quinn; Michael J Bottery; Harry Thompson; Ville-Petri Friman
Journal:  ISME J       Date:  2022-07-20       Impact factor: 11.217

4.  Stenotrophomonas maltophilia produces an EntC-dependent catecholate siderophore that is distinct from enterobactin.

Authors:  Megan Y Nas; Nicholas P Cianciotto
Journal:  Microbiology       Date:  2017-10-06       Impact factor: 2.777

5.  Ralstonia infection in cystic fibrosis.

Authors:  H D Green; R Bright-Thomas; D T Kenna; J F Turton; N Woodford; A M Jones
Journal:  Epidemiol Infect       Date:  2017-08-09       Impact factor: 4.434

6.  Rapid identification of Stenotrophomonas maltophilia by peptide nucleic acid fluorescence in situ hybridization.

Authors:  N Hansen; A K I Rasmussen; M J Fiandaca; K N Kragh; T Bjarnsholt; N Høiby; H Stender; L Guardabassi
Journal:  New Microbes New Infect       Date:  2014-03-25

7.  "Pathogen Eradication" and "Emerging Pathogens": Difficult Definitions in Cystic Fibrosis.

Authors:  Peter H Gilligan; Damian G Downey; J Stuart Elborn; Patrick A Flume; Sebastian Funk; Deirdre Gilpin; Timothy J Kidd; John McCaughan; B Cherie Millar; Philip G Murphy; Jacqueline C Rendall; Michael M Tunney; John E Moore
Journal:  J Clin Microbiol       Date:  2018-08-27       Impact factor: 5.948

8.  Advances in the Microbiology of Stenotrophomonas maltophilia.

Authors:  Joanna S Brooke
Journal:  Clin Microbiol Rev       Date:  2021-05-26       Impact factor: 50.129

9.  Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.

Authors:  Reshma Amin; Nikki Jahnke; Valerie Waters
Journal:  Cochrane Database Syst Rev       Date:  2020-03-18

10.  Comparative genomics of non-pseudomonal bacterial species colonising paediatric cystic fibrosis patients.

Authors:  Kate L Ormerod; Narelle M George; James A Fraser; Claire Wainwright; Philip Hugenholtz
Journal:  PeerJ       Date:  2015-09-15       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.